AI-Powered News Analysis•Compare coverage across the political spectrum
GoodPointsNews
Admin
Back to Dashboard
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis Reuters

October 4, 2026 at 10:18 PM Original source
1 agencies covered this story

Coverage by Political Leaning

See how different sides of the spectrum reported this story

Left
0 articles
No coverage
Lean Left
0 articles
No coverage
Center
1 articles
Lean Right
0 articles
No coverage
Right
0 articles
No coverage

Key People

No people linked to this story

Locations

Switzerland

Tags

Alentis biotechnology csL drug deal investment pharmaceuticals rare disease

All Coverage

CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis - Reuters
Reutersvia rss

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxPZG9HelZ5MGhEQ0N0OVhONHkzbFU0ZDlYN2FIcVdyR3BnUVVGWGRlVHZjRnlPNDhaci0yX05OTE8yTm9mZXlPcnplTGVhOGU5TlVmUm54UUFGYkQ3SFp4LU54TzBDTUtlbHpueFZKeUNRUnIyZHRYZG5Lcm9tejZmd25Fc0lITEFVbk9nNFo4WGJrUnNIUE1YS0VQc0ZBbjQ4NXdjb29GQ0VzWEJURmRyLW5JT2ZoQ2pHQlVZbWlJenhnYzFudmVnWjR0bV9FMGJobVEwelI1NTRyNVFYbVdmS2podFo?oc=5" target="_blank">CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

100%

Similar Stories

Related coverage based on topic and tags

Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal - Reuters

Viatris bets on non-opioid pain drugs with $1.65 billion Pacira deal Reuters

October 8, 2026 at 02:39 PM

Becton Dickinson pledges $19 billion US investment in deal with government - Reuters

Becton Dickinson pledges $19 billion US investment in deal with government Reuters

October 6, 2026 at 03:06 PM

McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal - Reuters

McKesson, CD&R to take infusion therapy provider Option Care private in $5.8 billion deal Reuters

October 6, 2026 at 04:30 PM

US FDA expands use of Novartis drug for chronic skin condition - Reuters

US FDA expands use of Novartis drug for chronic skin condition Reuters

October 7, 2026 at 04:51 PM

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports - Reuters

McKesson, CD&R near $5 billion-plus deal to buy Option Care, FT reports Reuters

October 5, 2026 at 09:09 PM

Wolfspeed secures $1.5 billion conditional loan commitment from US defense department - Reuters

Wolfspeed secures $1.5 billion conditional loan commitment from US defense department Reuters

October 7, 2026 at 09:09 PM